Mesothelioma treatment is individualized. The care team considers where the cancer began, stage, cell type, whether it can be removed surgically, heart and lung function, other health conditions, prior treatment and the patient’s preferences.
A plan may combine cancer-directed treatment with supportive or palliative care. Palliative care can begin at any stage and is not limited to end-of-life care.
Key takeaways
- Treatment may include surgery, systemic medicines, radiation, symptom-directed procedures or clinical trials.
- Some patients benefit from evaluation by a multidisciplinary team experienced with mesothelioma.
- The benefits and risks of major surgery require careful, individualized assessment.
- Approved and recommended drug options can change; this page requires frequent expert review.
- Supportive care addresses breathing, pain, nutrition, sleep and emotional wellbeing alongside cancer treatment.
Building a treatment plan
Mesothelioma care may involve medical oncologists, thoracic or surgical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, palliative-care clinicians, nurses and rehabilitation professionals. Ask whether the case will be reviewed by a multidisciplinary tumor board.
Important questions include the goal of treatment, expected benefit, possible side effects, alternatives, effect on quality of life and whether a clinical trial is available.
Surgery
Surgery may be considered for selected patients based on disease extent, tumor location, overall health and the experience of the treatment center. Operations for pleural disease may aim to remove visible tumor while preserving a lung or may involve removal of a lung and surrounding tissues. These are complex procedures with significant risks.
For selected peritoneal mesothelioma patients, cytoreductive surgery may be combined with heated chemotherapy delivered into the abdomen, often called HIPEC.
Surgery is not appropriate for everyone, and the terms used for operations can vary. Ask the surgeon to explain exactly which tissues would be removed, expected recovery, complication rates at that center and alternatives.
Chemotherapy and other systemic treatment
Systemic treatment travels through the bloodstream and can reach cancer cells throughout the body. Platinum-based chemotherapy combined with pemetrexed has long been used for mesothelioma. Other medicines may be added or substituted depending on the individual situation and current recommendations.
Possible side effects vary and may include fatigue, nausea, reduced blood counts, infection risk, kidney effects or nerve symptoms. The care team can explain prevention, monitoring and supportive medications.
Immunotherapy
Immunotherapy helps the immune system recognize or attack cancer. The combination of nivolumab and ipilimumab is among the options used for certain patients with advanced pleural mesothelioma. Immune-related side effects can affect organs such as the lungs, bowel, liver, skin and hormone-producing glands and may require prompt treatment.
Drug indications and treatment standards change. Patients should rely on their oncology team and current FDA labeling rather than using a general article to select treatment.
Radiation therapy
Radiation uses high-energy beams to damage cancer cells. It may be used in selected treatment plans or to relieve pain and other symptoms. Planning depends on tumor location and nearby organs, including healthy lung tissue.
Treatment for symptoms and quality of life
Procedures can drain fluid from the chest or abdomen. Pleurodesis or an indwelling catheter may help manage recurrent pleural fluid in appropriate patients. Medicines, rehabilitation and specialist palliative care can address pain, breathlessness, fatigue, appetite, anxiety and sleep.
Ask for palliative-care involvement early when symptoms, decision-making or caregiver strain would benefit from additional support.
Clinical trials
Clinical trials study new treatments, combinations, procedures or supportive-care approaches. Eligibility depends on factors such as disease type and stage, prior treatment, laboratory values and health. Participation is voluntary.
Questions to ask include:
- What is the purpose and phase of the study?
- Which costs are covered by the trial, sponsor or insurance?
- What are the known and unknown risks?
- What alternatives are available outside the trial?
- How often are visits required, and is travel assistance available?
Search current studies through ClinicalTrials.gov and the NCI clinical-trial resources.
Questions for the care team
- What is the goal of the recommended treatment?
- What benefit is reasonably expected, and how will response be measured?
- What are the major short- and long-term risks?
- Does the center treat mesothelioma regularly?
- Should I seek another pathology or treatment opinion?
- Could treatment affect eligibility for a later clinical trial?
- Who should I contact after hours about side effects?
Sources
- National Cancer Institute. Treatment for Mesothelioma Updated May 16, 2025.
- National Cancer Institute. Malignant Mesothelioma Treatment—Health Professional Version.
- National Cancer Institute. Mesothelioma Diagnosis and Prognosis Updated May 16, 2025.
- U.S. Food and Drug Administration. Oncology Center of Excellence and current drug labels.
Reviewed: [Add only after completed medical review] Next scheduled review: Quarterly and upon a material treatment change.